The BINDS program (Basis for Supporting Innovative Drug Discovery and Life Science Research), has been running since April 2017. The objective of this program is to establish an innovative platform to expedite the therapeutic applications of early-stage drug discovery and medical technology advances, by providing and sharing key technological infrastructure, including: synchrotron facilities at SPring-8 and the Photon Factory, cyro-electron microscopes, chemical compound libraries, and next-generation DNA sequencers. Specialists in state-of-the art technologies in the fields of structural biology, protein production, high-throughput screening (HTS) of chemical compounds, lead compound structural modifications and extensions, genome analysis, and in-silico screening, will support and assist the life science and drug development projects of researchers who submit their proposals to members of the BINDS program.